J M Zajecka - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

J M Zajecka

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

The Journal of Clinical Psychiatry|March 10, 2001

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patientsM D Lesem, J M Zajecka, R H Swift, et al.

Journal of the International Neuropsychological Society : JINS|May 1, 1995

Mood disturbance versus other symptoms of depression in multiple sclerosisD L Nyenhuis, S M Rao, J M Zajecka, et al.

Alimentary Pharmacology & Therapeutics|April 25, 2007

Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis CC L Raison, B J Woolwine, M F Demetrashvili, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

The Journal of Clinical Psychiatry|March 10, 2001

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patientsM D Lesem, J M Zajecka, R H Swift, et al.

Journal of the International Neuropsychological Society : JINS|May 1, 1995

Mood disturbance versus other symptoms of depression in multiple sclerosisD L Nyenhuis, S M Rao, J M Zajecka, et al.

Alimentary Pharmacology & Therapeutics|April 25, 2007

Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis CC L Raison, B J Woolwine, M F Demetrashvili, et al.

Pageof 2